Impaired Role of Epoxyeicosatrienoic Acids in the Regulation of Basal Conduit Artery Diameter During Essential HypertensionNovelty and Significance
In young healthy subjects, epoxyeicosatrienoic acids synthesized by endothelial cytochrome P450 epoxygenases maintain basal conduit artery diameter during altered NO availability. Whether this compensatory mechanism is effective during essential hypertension is unknown. Radial artery diameter, blood flow, and mean wall shear stress were determined in 14 nontreated essential hypertensive patients and 14 normotensive control subjects during 8 minutes of brachial infusion for inhibitors of cytochrome P450 epoxygenases (fluconazole, 0.4 µmol/min) and NO synthase (NG-monomethyl-l-arginine, 8 µmol/min) alone and in combination. In controls, the radial artery diameter was reduced by fluconazole (−0.034 ± 0.012 mm) and NG-monomethyl-l-arginine (−0.037 ± 0.010 mm) and to a larger extent by their combination (−0.137 ± 0.011 mm), demonstrating a synergic effect. In contrast, the radial diameter in hypertensive patients was not affected by fluconazole (0.010 ± 0.014 mm) but was reduced by NG-monomethyl-l-arginine (−0.091 ± 0.008 mm) to a larger extent than in controls. In parallel, NG-monomethyl-l-arginine decreased local plasma nitrite to a lesser extent in hypertensive patients (−14 ± 5 nmol/L) than in controls (−50 ± 10 nmol/L). Moreover, the addition of fluconazole to NG-monomethyl-l-arginine did not further decrease radial diameter in patients (−0.086 ± 0.011 mm). Accordingly, fluconazole significantly decreased local epoxyeicosatrienoic acid plasma level in controls (−2.0 ± 0.6 ng/mL) but not in patients (−0.9 ± 0.4 ng/mL). Inhibitors effects on blood flow and endothelium-independent dilatation to sodium nitroprusside were similar between groups. These results show that, in contrast to normotensive subjects, epoxyeicosatrienoic acids did not contribute to the regulation of basal conduit artery diameter and did not compensate for altered NO availability to maintain this diameter in essential hypertensive patients.
- Received June 27, 2012.
- Revision received July 12, 2012.
- Accepted September 20, 2012.
- © 2012 American Heart Association, Inc.